Zymeworks (ZYME) : 5-year performance

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 455
• incorporated in 2003 
• HQ: Vancouver, Canada.
• https://www.zymeworks.com

First day of trading Friday April 28, 2017

Vancouver, British Columbia-based biotherapeutics provider Zymeworks Inc has raised $58.5 million for its IPO after pricing its 4.5 million shares at $13 per share. The stock began trading April 28, 2017 on the New York Stock Exchange and on the Toronto Stock Exchange under the ticker symbol “ZYME";

Citigroup Global Markets Canada Inc., Barclays Capital Inc. and Wells Fargo Securities, LLC are the lead underwriters. Zymeworks'  pre-IPO backers include BDC Capital, Lumira Capital, CTI Life Sciences Fund, Fonds de solidarité FTQ, Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital and Merlin Nexus.

Postal Realty Trust (PSTL) : 3-year performance

Ticker: PSTL

 

Evoke Pharma (EVOK) : New FDA Market Exclusivity For Gimoti Nasal Spray

  

 

The FDA has granted new drug product exclusivity to Evoke Pharma Inc's (NASDAQ: EVOK) Gimoti (metoclopramide) nasal spray to relieve symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Evoke now has exclusive marketing rights over three (3) years from the original date of approval under the Hatch-Waxman Act to protect the product from generic drug competition.

In addition to the market exclusivity, Evoke maintains a robust patent estate, with currently two Orange book-listed patents that expire in 2029 and 2030.

The Company has also been granted gender-specific patents in the EU, Japan, and Mexico until 2032.

Furthermore, if approved, Evoke has other pending patent applications with individual expiration dates of 2032, 2037, and 2038.

IPOs this week : Apr 18 - 22, 2022 (wk 16)

IPOs expected to price

No new IPOs are expected to debut this week. 

IPO quiet period expirations

• AN2 Therapeutics (NASDAQ:ANTX) on April 19 

IPO lockup expirations

• Watch Stronghold Digital (SDIG), 
• Context Therapeutics (CNTX), 
• Portillo’s (NASDAQ:PTLO), P10 (PX), Vita Coco (COCO), Ventyx Bio (VTYX), Aris Water Solutions (ARIS), Xilio (XLO), Minerva Surgical (UTRS) and Infobird (IFBD) with insiders able to unload some shares.

Portillo's (PTLO): 6-month performance

 

PROCEPT BioRobotics (PRCT): 7-month performance

 

TPG Inc. (TPG) began trading on the Nasdaq on Thur 13 Jan 22

• Holding some $109 billion in assets, Texas- and San Francisco-based TPG becomes the fifth-largest publicly traded private equity firm in the U.S. by assets, again behind Blackstone ($619 billion), Apollo ($481 billion), Carlyle ($256 billion) and KKR ($252 billion).
• Founded in 1992, TPG in November announced plans to go public and owns outsize stakes in talent agency CAA, Vice Media and Spotify. Its long-awaited debut breathes new life into private equity public listings amid a massive boom in buyout deals.

Sector(s): Financial Services

Industry: Asset Management

Full Time Employees: 1,850

https://www.tpg.com

 

Ares Management (ARES) : 8-year performance

• May 2, 2014: Ares Management shares fell to close at $18.17, a decline of 4.4 percent from the IPO price. Ares cut the size of the offering to 11.4 million units from 18.2 million units, and the IPO priced below the estimated range of $21 to $23. The deal generated proceeds of $217 million and gave Ares a market cap of about $4 billion, or about 4.7x its 2013 net income of $850 million.
• https://www.aresmgmt.com/

 

MiNK Therapeutics (INKT) began trading on the Nasdaq on Fri 15 Oct 21

MiNK Therapeutics, Inc. (NASDAQ:INKT) is a clinical-stage biopharmaceutical company seeking to develop and commercialize off-the-shelf, allogeneic, invariant natural killer T (‘iNKT) cell therapies to treat cancer and other immune-mediated diseases. 

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 33
• HQ: New York, New York
• https://minktherapeutics.com

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Technology

iNKT cells are a distinct type of T cells, which in response to lipid antigenic stimulation, rapidly produce within minutes, large amounts of cytokines that can influence other immune cells. These are important immunoregulatory cells though comprising less than 1% of peripheral blood mononuclear cells (‘PBMCs) in the human blood pool. With their durable memory responses and rapid cytolytic features, iNKT cells have been shown to improve microbial and tumor immunity, while suppressing autoimmune disease and promoting tolerance. iNKT cell-derived cytokines and chemokines can modulate several other cell types, including NK cells, conventional CD4+ and CD

Anghami (ANGH) began trading on the Nasdaq on Fri 4 Feb 22

Anghami is the first legal music streaming platform and digital distribution company in the Arab world. It launched in November 2011 in Lebanon, providing unlimited Arabic and international music to stream and download for offline mode. Wikipedia

• Founder(s): Eddy Maroun; Elie Habib
• Headquarters: Abu Dhabi, United Arab Emirates
• Founded: 2012 in Lebanon
• Sector(s): Communication Services
• Industry: Entertainment
• Rival: Spotify (SPOT)
• Full Time Employees: 107
• https://www.anghami.com

First Arab tech company listed on the Nasdaq

Business combination with Vistas Media Acquisition (NASDAQ: VMAC)

 

 

 

 Founders Eddy Maroun and Elie Habib